Bisoprolol

Generic name
Bisoprolol
Brand name
ATC Code
C07AB07
Compare …

Bisoprolol

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

Pediatric pharmacokinetic studies in children have not been conducted. 

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Cardiac failure
  • Oral
    • 1 year up to 6 years
      • Initial dose: (Bisoprolol fumarate) 0.05 mg/kg/day in 1 dose
      • Maintenance dose: slowly titrate dose based on effect to max  10 mg/day in 1 dose

      • Expert-based recommendation: studies on bisoprol in children with heart failure have not been conducted. 

    • 6 years up to 18 years
      • Initial dose: (Bisoprolol fumarate) 1.25 mg/day in 1 dose
      • Maintenance dose: slowly titrate dose based on effect to max  10 mg/day in 1 dose

      • Expert-based recommendation: studies on bisoprol in children with heart failure have not been conducted. 

    • 6 years up to 18 years
      • Initial dose: (Bisoprolol fumarate) 1.25 mg/day in 1 dose
      • Maintenance dose: slowly titrate dose based on effect to max  10 mg/day in 1 dose

      • Expert-based recommendation: studies on bisoprol in children with heart failure have not been conducted. 

    • 1 year up to 6 years
      • Initial dose: (Bisoprolol fumarate) 0.05 mg/kg/day in 1 dose
      • Maintenance dose: slowly titrate dose based on effect to max  10 mg/day in 1 dose

      • Expert-based recommendation: studies on bisoprol in children with heart failure have not been conducted. 
Hypoplastic left heart syndrome
  • Oral
    • Term neonate
      • Initial dose: (Bisoprolol fumarate) 0.05 mg/kg/day in 1 dose
      • Maintenance dose: titrate dose based on effect (heart rate guided) tot max 0.2 mg/kg/day in 1 dose

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

BETA BLOCKING AGENTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Beta blocking agents, non-selective
C07AA05
C07AA07
Beta blocking agents, selective
C07AB03
C07AB09
C07AB02
Alpha and beta blocking agents
C07AG02
C07AG01

References

  1. MIenert T. et al., Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart., Paediatr Drugs, 2021, 23(2), 195-202
  2. Sorof JM, et al., Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial., Pediatr Nephrol., 2002, 17(5), 345-50
  3. Chaturvedi S, et al, Pharmacological interventions for hypertension in children., Cochrane Database Syst Rev., 2014, (2), CD008117.
  4. Bourke JP, et al., Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial., Neurol Clin Pract., 2021, 11(5), e661-e8.

Changes

Therapeutic Drug Monitoring


Overdose